KRAS and lung adenocarcinoma: Mutant Kras copy gains are positively selected for during tumor progression in a p53 mutant background47; however, our results analyzing survival in patients indicate that unlike KRAS/LKB1 mutant patients, high levels of KRAS in TP53-mutant lung adenocarcinoma patients may not be a key factor in determining overall survival.